Geron downgraded by B. Riley Securities with a new price target
$GERN
Biotechnology: Pharmaceutical Preparations
Health Care
B. Riley Securities downgraded Geron from Buy to Neutral and set a new price target of $2.00 from $3.50 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/8/2025 | $1.50 | Sector Outperform → Sector Perform | Scotiabank |
| 2/27/2025 | $3.50 → $2.00 | Buy → Neutral | B. Riley Securities |
| 2/26/2025 | Buy → Neutral | H.C. Wainwright | |
| 11/5/2024 | $8.00 | Buy | H.C. Wainwright |
| 10/16/2024 | Sector Outperform | Scotiabank | |
| 9/9/2024 | $7.00 | Outperform | Leerink Partners |
| 4/30/2024 | $4.50 | Outperform → Neutral | Robert W. Baird |
| 4/29/2024 | $10.00 | Buy | TD Cowen |
Geron Corporation (NASDAQ:GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 1,116,000 shares of its common stock, consisting of stock options to purchase an aggregate of 744,000 shares of common stock, and restricted stock units ("RSUs") representing an aggregate of 372,000 shares of common stock, to 16 newly hired employees as an inducement material to their acceptance of employment with Geron. The stock options and RSUs were granted on June 17, 2025. The stock options have an exercise price of $1.45 per share, which is equal to the closing price of Geron common stock on the grant date, have a ten-year term and
New post-hoc analyses from the IMerge trial show clinical benefit with RYTELO across patients with lower-risk myelodysplastic syndromes (LR-MDS), regardless of ring sideroblast status, baseline serum erythropoietin (sEPO) level, or prior therapy use Health-related quality-of-life (QOL) data and results on time without transfusion reliance (TWiTR) provide deeper insights into patient-centric outcomes with RYTELO in LR-MDS Updates on ongoing IMpactMF and IMproveMF trials of imetelstat show progress in advancing the science of telomerase inhibition in the treatment of myelofibrosis Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by cha
Geron Corporation (NASDAQ:GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 411,000 shares of its common stock, consisting of stock options to purchase an aggregate of 274,000 shares of common stock, and restricted stock units ("RSUs") representing an aggregate of 137,000 shares of common stock, to six newly hired employees as an inducement material to their acceptance of employment with Geron. The stock options and RSUs were granted on May 16, 2025. The stock options have an exercise price of $1.27 per share, which is equal to the closing price of Geron common stock on the grant date, have a 10-year term and vest
Scotiabank downgraded Geron from Sector Outperform to Sector Perform and set a new price target of $1.50
B. Riley Securities downgraded Geron from Buy to Neutral and set a new price target of $2.00 from $3.50 previously
H.C. Wainwright downgraded Geron from Buy to Neutral
4 - GERON CORP (0000886744) (Issuer)
4 - GERON CORP (0000886744) (Issuer)
4 - GERON CORP (0000886744) (Issuer)
8-K - GERON CORP (0000886744) (Filer)
SCHEDULE 13G/A - GERON CORP (0000886744) (Subject)
10-Q - GERON CORP (0000886744) (Filer)